- Home
- OSW vs GLPG Comparison
OSW vs GLPG Comparison
Compare OSW & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSW
- GLPG
- Stock Information
- Founded
- OSW 2017
- GLPG 1999
- Country
- OSW Bahamas
- GLPG Belgium
- Employees
- OSW N/A
- GLPG N/A
- Industry
- OSW Hotels/Resorts
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- OSW Consumer Discretionary
- GLPG Health Care
- Exchange
- OSW Nasdaq
- GLPG Nasdaq
- Market Cap
- OSW 2.3B
- GLPG 2.1B
- IPO Year
- OSW N/A
- GLPG 2005
- Fundamental
- Price
- OSW $21.82
- GLPG $32.02
- Analyst Decision
- OSW Strong Buy
- GLPG Sell
- Analyst Count
- OSW 3
- GLPG 4
- Target Price
- OSW $22.67
- GLPG $25.33
- AVG Volume (30 Days)
- OSW 488.7K
- GLPG 198.2K
- Earning Date
- OSW 10-29-2025
- GLPG 10-29-2025
- Dividend Yield
- OSW 0.73%
- GLPG N/A
- EPS Growth
- OSW 32.03
- GLPG N/A
- EPS
- OSW 0.68
- GLPG N/A
- Revenue
- OSW $919,258,000.00
- GLPG $323,674,692.00
- Revenue This Year
- OSW $8.52
- GLPG N/A
- Revenue Next Year
- OSW $8.82
- GLPG N/A
- P/E Ratio
- OSW $32.09
- GLPG N/A
- Revenue Growth
- OSW 8.51
- GLPG 5.43
- 52 Week Low
- OSW $14.21
- GLPG $22.36
- 52 Week High
- OSW $23.28
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- OSW 46.75
- GLPG 49.28
- Support Level
- OSW $21.55
- GLPG $30.88
- Resistance Level
- OSW $22.68
- GLPG $33.63
- Average True Range (ATR)
- OSW 0.63
- GLPG 0.69
- MACD
- OSW -0.09
- GLPG -0.02
- Stochastic Oscillator
- OSW 17.05
- GLPG 41.45
About OSW OneSpaWorld Holdings Limited
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.